Skip to main content
Clinical Trials/NCT00452608
NCT00452608UnknownPhase 2

Use of Statins in Modulation of Inflammatory Answer in Septic Patients

Hospital de Clinicas de Porto Alegre1 site in 1 country80 target enrollmentStarted: December 2006Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 2
Enrollment
80
Locations
1
Primary Endpoint
action in inflammmatory biologic makers

Study Overview

Brief Summary

The purpose of this study is to determine whether atorvastatin can improve the inflammatory answer in the septic patients

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
15 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • clinical diagnosis of several sepsis or shock septic
  • no more than twenty four hours than diagnosis

Exclusion Criteria

  • use of statins in the last thirty days
  • unequivocal indication for statin treatment
  • active treatment with imunosuppressors drugs
  • High risk of rhabdomyolysis: multiple trauma, crush injuries, baseline creatinine kinase > three times upper limit of normal
  • diagnosis of AIDS
  • unable to receive enteral medications
  • pregnancy
  • expected survival of less than 48 hours

Arms & Interventions

amido pill

Placebo Comparator

Intervention: amido pill (Drug)

atorvastatina

Experimental

atrovastatina 80 mg/d by mouth for 10 days

Intervention: atorvastatina (Drug)

Outcomes

Primary Outcomes

action in inflammmatory biologic makers

Time Frame: 24h; 72h; 10 days

valuation of flow-mediated vasodilation of the brachial artery

Time Frame: 24h; 72; 10 days

Secondary Outcomes

  • mortality(at end)
  • time of permanence in intensive care unity(at end)
  • time of permanence in mechanical ventilation(at end)

Investigators

Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Statin for Immunomudulation in Sepsis | Clinical Trial